A tumor-homing peptide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Product Categories

Product Type

Biochemicals
Peptides

Research Area

Cancer
Cardiovascular System
Blood
Thrombosis

CREKA (trifluoroacetate salt)

Item No. 44492

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(2S,5S,8S,11S,14R,17S)-17-amino-5-(4-aminobutyl)-37-azido-8-(2-carboxyethyl)-11-(3-guanidinopropyl)-14-(mercaptomethyl)-2-methyl-4,7,10,13,16,23-hexaoxo-26,29,32,35-tetraoxa-3,6,9,12,15,22-hexaazaheptatriacontanoic acid, 2,2,2-trifluoroacetic acid
Molecular Formula
C40H74N14O14S • CF3COOH
Formula Weight
1121.2
Purity
≥95%
Formulation (Request formulation change)
A solid
Peptide Sequence
Cys-Arg-Glu-Lys-Ala
Solubility(Learn about Variance in Solubility)
DMSO: Soluble: ≥ 10 mg/mlPBS (pH 7.2): Soluble: ≥ 10 mg/ml
SMILES
O=C(N[C@@H](CS)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)[C@H](CCCCNC(CCOCCOCCOCCOCCN=[N+]=[N-])=O)N.O=C(O)C(F)(F)F
InChi Code
InChI=1S/C40H74N14O14S.C2HF3O2/c1-26(39(63)64)49-35(59)28(8-2-4-13-41)50-37(61)30(10-11-33(56)57)52-36(60)29(9-6-15-47-40(43)44)51-38(62)31(25-69)53-34(58)27(42)7-3-5-14-46-32(55)12-17-65-19-21-67-23-24-68-22-20-66-18-16-48-54-45;3-2(4,5)1(6)7/h26-31,69H,2-25,41-42H2,1H3,(H,46,55)(H,49,59)(H,50,61)(H,51,62)(H,52,60)(H,53,58)(H,56,57)(H,63,64)(H4,43,44,47);(H,6,7)/t26-,27-,28-,29-,30-,31-;/m0./s1
InChi Key
CWWRZFSWGWZLCP-JFSSMAGCSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $54

    Add

    10 mg

    $86

    Add

    25 mg

    $162

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    CREKA is a linear 5-amino acid tumor-homing peptide that recognizes fibrin-fibronectin complexes.1,2,3 It has been conjugated to lipid nanoparticles (LNPs) for the targeting of fibrin-fibronectin complexes in vitro and in mouse xenograft models.1,3 CREKA has also been used in the synthesis of fusion proteins for the targeting of fibrin-fibronectin complexes in mouse thrombosis models.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Zhang, N., Ru, B., Hu, J., et al. Recent advances of CREKA peptide-based nanoplatforms in biomedical applications. J. Nanobiotechnology 21(1), 77 (2023).

    2. Hajizade, M.S., Raee, M., Faraji, S.N., et al. Targeted drug delivery to the thrombus by fusing streptokinase with a fibrin-binding peptide (CREKA): An in silico study. Ther. Deliv. 15(6), 399-411 (2024).

    3. Kruse, A.M., Meenach, S.A., Anderson, K.W., et al. Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for hyperthermia applications. Acta Biomater. 10(6), 2622-2629 (2014).